Chemo and Immunotherapy before Liver Cancer Surgery
Part of Cancer, Digestive system clinical trials.
This trial tests giving chemotherapy directly into the liver artery (HAIC) combined with immunotherapy before surgery for liver cancer that can be removed but is too large or numerous for standard treatment. The goal is to shrink the tumor and improve surgery results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with liver cancer (hepatocellular carcinoma) that can be surgically removed, but is too big or has too many spots for standard criteria.
- You have not had any prior treatment for your liver cancer (like chemotherapy, targeted therapy, or immunotherapy).
- Your liver function is good (Child-Pugh Class A) and you are generally active (ECOG score 0).
- You do not have active hepatitis B or C virus at high levels, bleeding problems, autoimmune diseases, or other uncontrolled health issues.
- You are willing to use effective birth control if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of liver-directed chemotherapy (HAIC), an immunotherapy drug (sintilimab), and a drug that blocks blood vessel growth (bevacizumab biosimilar) for advanced liver cancer that hasn't been treated with systemic therapy before. The goal is to see if this triple therapy can shrink or control the cancer.
This study tests whether adding two immunotherapy drugs (durvalumab and tremelimumab) plus radiation before surgery works better than radiation alone before surgery for people with resectable liver cancer. It's for those with a single tumor (or a few small nearby spots) that hasn't spread.
This trial tests if giving a combination of drugs (apatinib and camrelizumab) along with a procedure called TACE before surgery can help treat a certain type of liver cancer. The goal is to shrink the tumor before the operation to improve outcomes.
This trial tests whether a targeted chemotherapy infusion directly into the liver's main artery (HAIC) after surgery can prevent liver cancer from coming back. It is for people with certain high-risk features, like a large tumor or cancer in blood vessels, who have had their tumor completely removed.
This trial tests giving two immunotherapy drugs directly into the tumor before surgery for liver cancer. It aims to see if this approach can shrink the tumor and improve outcomes for patients who are candidates for surgery.
This trial tests whether giving a combination of two immunotherapy drugs before surgery can lower the chance of liver cancer coming back in people who have high-risk features. It may help patients with early-stage liver cancer that can be removed surgically.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.